ReviewMolecular diagnosis & therapy2013
Commercial multiplex technologies for the microbiological diagnosis of sepsis.
Review in Molecular diagnosis & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Diagnostic utility of procalcitonin in determining Gram-negative and Gram-positive bacterial bloodstream infections: a single-centre study from South India.Frontiers in medicine · 2026Article
- Review
- Exploring the Utility of Multiplex Infectious Disease Panel Testing for Diagnosis of Infection in Different Body Sites: A Joint Report of the Association for Molecular Pathology, American Society for Microbiology, Infectious Diseases Society of America, and Pan American Society for Clinical Virology.The Journal of molecular diagnostics : JMD · 2023Review
- Article
- Advances in the screening of antimicrobial compounds using electrochemical biosensors: is there room for nanomaterials?Analytical and bioanalytical chemistry · 2023Review
- Article
- Tracking bacterial DNA patterns in septic progression using 16s rRNA gene amplicon sequencing analysis.International journal of clinical and experimental pathology · 2021Article
- Comprehensive Pathogen Identification, Antibiotic Resistance, and Virulence Genes Prediction Directly From Simulated Blood Samples and Positive Blood Cultures by Nanopore Metagenomic Sequencing.Frontiers in genetics · 2021Article
- Point of care technologies for sepsis diagnosis and treatment.Lab on a chip · 2019Review
- Non-culture based assays for the detection of fungal pathogens.Journal de mycologie medicale · 2018Review
- DNA extraction from primary liquid blood cultures for bloodstream infection diagnosis using whole genome sequencing.Journal of medical microbiology · 2018Article
- Nonconventional Markers of Sepsis.EJIFCC · 2017Article
- Elasto-inertial microfluidics for bacteria separation from whole blood for sepsis diagnostics.Journal of nanobiotechnology · 2017Article
- Clinical Significance of Molecular Diagnostic Tools for Bacterial Bloodstream Infections: A Systematic Review.Interdisciplinary perspectives on infectious diseases · 2016Review
- Real-time polymerase chain reaction and culture in the diagnosis of invasive group B streptococcal disease in infants: a retrospective study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2015Article
- Balancing Enthusiasm for Innovative Technologies with Optimizing Value: An Approach to Adopt New Laboratory Tests for Infectious Diseases Using Bloodstream Infections as Exemplar.Open forum infectious diseases · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
In patients with suspected sepsis, rapid and accurate diagnosis of the causative infectious agent is critical. Although clinicians often use empiric antimicrobial therapy until the blood cultures are available to potentially adjust treatment, this approach is often not optimum for patient care. Recently, several commercial molecular multiplex technologies have shown promise for fast and comprehensive diagnosis of microorganisms and their antimicrobial resistance signatures. While one class of multiplex technologies is directed at improving the speed and diagnostic information obtained from positive blood cultures, the other identifies the causative microorganisms directly from clinical blood samples. This review provides an overview of these molecular technologies and describes their performance capabilities compared to standard blood cultures and in some cases to each other. We discuss the current clinical impact, limitations, and likely futures advances these multiplex technologies may have in guiding the management of patients with sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.